Y Intercept Hong Kong Ltd Takes $555,000 Position in Bausch + Lomb Co. (NYSE:BLCO)

Y Intercept Hong Kong Ltd acquired a new position in shares of Bausch + Lomb Co. (NYSE:BLCO) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 28,791 shares of the company’s stock, valued at approximately $555,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BLCO. River Road Asset Management LLC grew its position in Bausch + Lomb by 4.4% in the 3rd quarter. River Road Asset Management LLC now owns 2,020,414 shares of the company’s stock valued at $38,974,000 after buying an additional 85,987 shares in the last quarter. Whitebox Advisors LLC lifted its stake in shares of Bausch + Lomb by 28.2% in the 2nd quarter. Whitebox Advisors LLC now owns 1,545,946 shares of the company’s stock worth $22,447,000 after acquiring an additional 339,643 shares during the period. Clearline Capital LP boosted its holdings in shares of Bausch + Lomb by 136.8% in the second quarter. Clearline Capital LP now owns 712,055 shares of the company’s stock valued at $10,339,000 after acquiring an additional 411,404 shares in the last quarter. Point72 Europe London LLP increased its stake in shares of Bausch + Lomb by 28.9% during the second quarter. Point72 Europe London LLP now owns 653,492 shares of the company’s stock valued at $9,489,000 after acquiring an additional 146,583 shares during the period. Finally, Point72 Asset Management L.P. raised its holdings in Bausch + Lomb by 31.0% during the second quarter. Point72 Asset Management L.P. now owns 647,156 shares of the company’s stock worth $9,397,000 after purchasing an additional 153,000 shares in the last quarter. 11.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on BLCO. Needham & Company LLC reaffirmed a “hold” rating on shares of Bausch + Lomb in a research note on Thursday, October 31st. Wells Fargo & Company raised their target price on Bausch + Lomb from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Bank of America reaffirmed an “underperform” rating and set a $18.00 target price on shares of Bausch + Lomb in a report on Thursday. Morgan Stanley downgraded shares of Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price target for the company. in a report on Monday, December 2nd. Finally, Royal Bank of Canada lifted their price objective on shares of Bausch + Lomb from $20.00 to $23.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $20.58.

Bausch + Lomb Stock Down 0.1 %

BLCO stock opened at $18.60 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.57 and a quick ratio of 0.95. The firm has a market capitalization of $6.55 billion, a P/E ratio of -17.71, a P/E/G ratio of 1.74 and a beta of 0.43. Bausch + Lomb Co. has a 52-week low of $13.16 and a 52-week high of $21.69. The company’s 50 day simple moving average is $19.87 and its 200-day simple moving average is $17.53.

Bausch + Lomb (NYSE:BLCO) last announced its earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.01. Bausch + Lomb had a negative net margin of 7.86% and a positive return on equity of 3.17%. The company had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period in the previous year, the business earned $0.22 EPS. The company’s revenue was up 18.8% on a year-over-year basis. As a group, equities research analysts anticipate that Bausch + Lomb Co. will post 0.6 EPS for the current year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.